Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Sees Large Growth in Short Interest

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 134,469 shares, a growth of 27,740.4% from the April 30th total of 483 shares. Based on an average daily volume of 525,489 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.2% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a research note on Friday, May 1st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Trading Down 3.1%

NASDAQ:HKPD opened at $0.53 on Friday. The stock has a 50-day simple moving average of $0.61 and a two-hundred day simple moving average of $0.74. Hong Kong Pharma Digital Technology has a 52-week low of $0.37 and a 52-week high of $2.76. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.93 and a quick ratio of 2.73.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last released its quarterly earnings results on Wednesday, March 18th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $3.57 million for the quarter.

Institutional Trading of Hong Kong Pharma Digital Technology

An institutional investor recently bought a new position in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new stake in shares of Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology as of its most recent filing with the Securities & Exchange Commission.

Hong Kong Pharma Digital Technology Company Profile

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.